Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.48 |
| ▸ | EGLN2 | Q96KS0 | 14/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1219877 | 0.87 | EGLN1 (0.69) | EGLN1EGLN2 | |
| SCHEMBL29726498 | 0.80 | EGLN1 (0.70) | EGLN1EGLN2 | |
| SCHEMBL21361727 | 0.80 | EGLN1 (0.70) | EGLN1EGLN2 | |
| SCHEMBL5076142 | 0.78 | EGLN1 (0.54) | TDP1L3MBTL1EGLN1EGLN2 | |
| SCHEMBL27735218 | 0.77 | TDP1 (0.51) | TDP1L3MBTL1KMT2AEGLN1EGLN2 | |
| SCHEMBL26691598 | 0.75 | TDP1 (0.68) | TDP1L3MBTL1KMT2AMAPTMEN1 | |
| SCHEMBL3782146 | 0.75 | EGLN1 (0.66) | EGLN1EGLN2 | |
| SCHEMBL15272286 | 0.74 | EGLN2 (0.48) | KMT2AEGLN1EGLN2 | |
| SCHEMBL3781574 | 0.74 | THRA (0.72) | EGLN1EGLN2 | |
| SCHEMBL3776368 | 0.74 | EGLN1 (0.72) | EGLN1EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331362-A1 | Treatment method for anemia | FIBROGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-1893186-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006133391-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| US-20060276477-A1 | Treatment method for anemia | FIBROGEN, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331362-A1 | Treatment method for anemia | THPO, EPOR, MPL | TDP1 4695/4885L3MBTL1 3460/4885KMT2A 2325/4885 |
| US-20060276477-A1 | Treatment method for anemia | THPO, EPOR, MPL | TDP1 4695/4885L3MBTL1 3460/4885KMT2A 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.